Published online Nov 10, 2015. doi: 10.4253/wjge.v7.i16.1230
Peer-review started: July 30, 2015
First decision: August 31, 2015
Revised: September 8, 2015
Accepted: September 29, 2015
Article in press: September 30, 2015
Published online: November 10, 2015
Processing time: 106 Days and 14.3 Hours
A recent paper by Boal Carvalho et al demonstrates the potential of PillCam COLON 2© (PCC2) as a pan-enteric investigation in Crohn’s disease (CD). Our own prospective data in patients with known CD also shows good correlation between PCC2 and small/large bowel investigations (R = 0.896, P < 0.0004/R = 0.6667, P < 0.035). Larger studies are warranted to prospectively validate the use of PCC2 in the investigation and monitoring of both small and large bowel CD.
Core tip: Mucosal healing has been shown to reduce the need for surgery and hospitalisation in patients with Crohn’s disease. Currently, assessing small bowel and colonic mucosal healing requires separate imaging/endoscopic modalities. Recent data suggests that the PillCam Colon 2© (PCC2) is capable of assessing mucosal healing of the small intestine and colon in a single, non-invasive test. Our own prospective data corroborates these findings demonstrating good correlation between investigations. Larger studies assessing the viability of PCC2 as a pan-enteric investigation are warranted.